Progranulin levels in blood in Alzheimer's disease and mild cognitive impairment

Autor: Giovanni Coppola, Anna Karydas, Bruce L. Miller, Ginette Serrero, Deepika Dokuru, Zhongan Yang, Adam L. Boxer, Daniel Nachun, Binbin Yue, Yonatan A. Cooper
Jazyk: angličtina
Rok vydání: 2018
Předmět:
0301 basic medicine
Apolipoprotein E
Oncology
medicine.medical_specialty
Aging
Clinical Sciences
Neurodegenerative
Alzheimer's Disease
03 medical and health sciences
0302 clinical medicine
Polymorphism (computer science)
Internal medicine
Gene expression
mental disorders
medicine
Genetics
Acquired Cognitive Impairment
SNP
2.1 Biological and endogenous factors
Aetiology
Alzheimer's Disease Related Dementias (ADRD)
Research Articles
business.industry
General Neuroscience
Haplotype
Alzheimer's Disease Neuroimaging Initiative
Neurosciences
Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)
Methylation
medicine.disease
3. Good health
Brain Disorders
030104 developmental biology
DNA methylation
Neurological
Dementia
Neurology (clinical)
business
030217 neurology & neurosurgery
Frontotemporal dementia
Research Article
Zdroj: Cooper, YA; Nachun, D; Dokuru, D; Yang, Z; Karydas, AM; Serrero, G; et al.(2018). Progranulin levels in blood in Alzheimer's disease and mild cognitive impairment. ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 5(5), 616-629. doi: 10.1002/acn3.560. UCLA: Retrieved from: http://www.escholarship.org/uc/item/7rx4w3n8
Annals of clinical and translational neurology, vol 5, iss 5
Annals of Clinical and Translational Neurology
Popis: Author(s): Cooper, Yonatan A; Nachun, Daniel; Dokuru, Deepika; Yang, Zhongan; Karydas, Anna M; Serrero, Ginette; Yue, Binbin; Alzheimer's Disease Neuroimaging Initiative; Boxer, Adam L; Miller, Bruce L; Coppola, Giovanni | Abstract: ObjectiveChanges in progranulin (GRN) expression have been hypothesized to alter risk for Alzheimer's disease (AD). We investigated the relationship between GRN expression in peripheral blood and clinical diagnosis of AD and mild cognitive impairment (MCI).MethodsPeripheral blood progranulin gene expression was measured, using microarrays from Alzheimer's (n = 186), MCI (n = 118), and control (n = 204) subjects from the University of California San Francisco Memory and Aging Center (UCSF-MAC) and two independent published series (AddNeuroMed and ADNI). GRN gene expression was correlated with clinical, demographic, and genetic data, including APOE haplotype and the GRN rs5848 single-nucleotide polymorphism. Finally, we assessed progranulin protein levels, using enzyme-linked immunosorbent assay, and methylation status using methylation microarrays.ResultsWe observed an increase in blood progranulin gene expression and a decrease in GRN promoter methylation in males (P = 0.007). Progranulin expression was 13% higher in AD and MCI patients compared with controls in the UCSF-MAC cohort (F2,505 = 10.41, P = 3.72*10-5). This finding was replicated in the AddNeuroMed (F2,271 = 17.9, P = 4.83*10-8) but not the ADNI series. The rs5848 SNP (T-allele) predicted decreased blood progranulin gene expression (P = 0.03). The APOE4 haplotype was positively associated with progranulin expression independent of diagnosis (P = 0.04). Finally, we did not identify differences in plasma progranulin protein levels or gene methylation between diagnostic categories.InterpretationProgranulin mRNA is elevated in peripheral blood of patients with AD and MCI and its expression is associated with numerous genetic and demographic factors. These data suggest a role in the pathogenesis of neurodegenerative dementias besides frontotemporal dementia.
Databáze: OpenAIRE